Contact:
At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992
or
At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672
or
General Inquiries
Kathy Waller
312.640.6696
or
Media Inquiries
Tim Grace
312.640.6741 |
RegeneRx to Present at the 3rd Annual ThinkEquity Growth Conference
RegeneRx to Present at the 3rd Annual ThinkEquity Growth Conference
September 6, 2005 — Bethesda, Md
RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN) (www.regenerx.com) announced today that it is presenting at the 3rd Annual ThinkEquity Growth Conference, on September 13, at 9:00 a.m. Pacific time, in San Francisco, California. The presentation will be made by J.J. Finkelstein, RegeneRx's president and CEO and will be webcast by Wall Street Webcasting (a division of The Wall Street Transcript). A link will be provided on the Company's website prior to the presentation or interested parties may type the following address in their browsers: http://www.wsw.com/webcast/tep6/rgn/.
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx (www.regenerx.com) is a biopharmaceutical company developing Tß4 as a platform technology for the treatment of acute and chronic wounds and for a variety of human diseases involving tissue and organ repair under an exclusive world-wide license from the National Institutes of Health. The company holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, including the treatment and prevention of cardiac and neurological injuries, as well as patents related to the treatment of septic shock. RegeneRx is currently sponsoring three Phase II dermal wound healing clinical trials and has targeted cardiac and ophthalmic wound healing trials in 2006 as part of its ongoing clinical development program.
Safe Harbor Statement
The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the regulatory approval process and the ongoing and prospective development and commercialization of T?4 and possible future benefits to the Company, its stockholders, and patients. Due to the nature of clinical trials, product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.
 Back To 2005 Press Release Archives
|
